Cullinan Therapeutics Presents Initial Clinical Data for CLN-978, a CD19xCD3 T Cell Engager, at the EULAR 2026 Congress
Cullinan Therapeutics presented initial Phase 1 data for CLN-978 at EULAR 2026, showing clinical benefit and remissions in patients with systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). In the SLE cohort, 71% of patients with sufficient follow-up saw a significant reduction in disease activity scores, and half of those achieved remission. Deep, dose-dependent B-cell depletion was observed in both blood and tissue. The RA cohort showed 71% improvement in disease activity, with one patient achieving remission after a single dose.
Key figures
- Drug Name
- CLN-978
- Phase Of Trial
- Phase 1
- Ra patients
- 11
- Sle patients
- 18
- Crs grade 3 count
- 1
- Max target dose tested
- 45 µg
- B cell depletion ra pct
- 67%
- Sle doris remission pct
- 50% of those with >=4 weeks follow-up (5/10 with reduction)
- B cell depletion sle pct
- 82%
- Total patients evaluated
- 29
- Ra das28 esr remission count
- 1
- Sle hsladai reduction ge4 pct
- 71%
- Ra disease activity improvement pct
- 71%
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.